Advertisement
News
Subscribe to MDT Magazine News

Hanger Orthopedic Group, Inc. Announces Pricing of Underwritten Public Offering by Shareholder

December 10, 2010 7:34 am | by Bio-Medicine.Org | Comments

AUSTIN, Texas, Dec. 10, 2010 /- Hanger Orthopedic Group, Inc. (NYSE: HGR ) announced today the pricing of the previously announced public offering of 2,000,000 shares of its common stock by Ares Corporate Opportunities Fund, L.P. at a public offering price of $20.00 per share.  The...

TOPICS:

SABCS 2010: Interview with Carlos L. Arteaga, M.D.

December 10, 2010 7:34 am | by AACR | Comments

Dr. Arteaga discusses targeted drugs for breast cancer, endocrine resistance, clinical trial enrollment criteria and his reactions to some of the important presentations at this year's symposium.

TOPICS:

SABCS 2010: Interview with Chi Van Dang, M.D., Ph.D.

December 10, 2010 7:34 am | by AACR | Comments

Dr. Dang discusses the major points of his plenary session, “Oncogenic Reprogramming of Metabolism and Therapy,” including how oncogenic alterations in cancers lead to altered tumor metabolism, and the function of the c-myc oncoprotein, which has emerged as a central oncogenic switch in...

TOPICS:
Advertisement

SABCS 2010: Interview with Stacy L. Moulder, M.D.

December 10, 2010 7:33 am | by AACR | Comments

Dr. Moulder talks about her research on PARP inhibitors for hard-to-treat breast cancers, such as triple-negative breast cancer, and the collaborative team that continues this line of research.

TOPICS:

SABCS 2010: Interview with George W. Sledge Jr., M.D.

December 10, 2010 7:33 am | by AACR | Comments

Dr. Sledge talks about the results of the first large nationwide study on the use of Taxol for advanced breast cancer, his perspective on new therapies for breast cancer, and his goals as president of the American Society of Clinical Oncology.

TOPICS:

BG Medicine plans IPO of up to $71.2M

December 10, 2010 6:33 am | by Mass High Tech: The Journal of New England Technology | Comments

BG Medicine Inc., the Waltham-based developer of biomarker-based diagnostic tools, is expected to announce an initial public offering of up to $71.2 million, according to a regulatory filing. The 4.7 million shares, planned for between $13 and $15, is expected to be priced next week, a...

2010 SABCS: AZURE Trial Teleconference

December 10, 2010 6:32 am | by AACR | Comments

Robert E. Coleman, M.D., professor and honorary consultant medical oncologist at the Cancer Research Center, Academic Unit Medical of Clinical Oncology at Weston Park Hospital in Sheffield, England, presents the results of the AZURE (Adjuvant Zoledronic Acid to Reduce Recurrence) trial at...

TOPICS:

Boston Micromachines, Bridger Photonics sign consulting deal

December 10, 2010 5:33 am | by I-Micronews | Comments

Boston Micromachines Corp. (BMC) announced Monday that it has signed a consulting agreement with Bridger Photonics Inc. to quantitatively assess a new MEMS membrane deformable mirror design using BMC?s facilities.

Advertisement

Mylan Receives Approval for Generic Version of Adalat® CC Tablets

December 10, 2010 5:32 am | by Bio-Medicine.Org | Comments

PITTSBURGH, Dec. 10, 2010 /- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nifedipine Extended-release Tablets USP,...

TOPICS:

Tomophase OCTIS(TM) Receives FDA 510(K) Clearance to Market

December 10, 2010 5:31 am | by Bio-Medicine.Org | Comments

BURLINGTON, Mass., Dec. 10, 2010 /- Tomophase Corporation, developer of the non-invasive Optical Coherence Tomography Imaging System (OCTIS™) and other devices, announced today that it has received FDA 510(k) clearance to market OCTIS. Tomophase is a leader in the development of OCT...

TOPICS:

Combination Therapy Reduced HER2-positive Breast Cancers

December 10, 2010 4:35 am | by AACR | Comments

SAN ANTONIO - A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held...

TOPICS:

Pertuzumab and Trastuzumab Combination Improved Efficacy for Women With HER2-positive Breast Cancer

December 10, 2010 4:34 am | by AACR | Comments

SAN ANTONIO - The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.

TOPICS:

Phase III Study Compared Neoadjuvant Therapy with Lapatinib or Trastuzumab for Early Breast Cancer

December 10, 2010 4:34 am | by AACR | Comments

SAN ANTONIO - Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer...

TOPICS:

NewCardio Presents Results for Cardiac Safety Research Consortium Blinded Drug Safety Study

December 10, 2010 4:33 am | by Bio-Medicine.Org | Comments

SANTA CLARA, Calif., Dec. 10, 2010 /- NewCardio, Inc., (OTC Bulletin Board: NWCI ) a cardiovascular diagnostic solutions developer, today presented the results from a blinded drug safety study conducted by the Cardiac Safety Research Consortium (CSRC) to evaluate the performance of...

TOPICS:

Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension

December 10, 2010 4:33 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Dec. 10, 2010 /- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading